Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Telomir Pharmaceuticals, Inc. ( (TELO) ) is now available.
Telomir Pharmaceuticals has announced promising preclinical results for its lead compound, Telomir-1, which demonstrated the ability to restore mitochondrial function in diseased human cell lines without causing cell proliferation. The study, conducted in collaboration with Smart Assays Biotechnologies, highlighted Telomir-1’s unique profile of enhancing mitochondrial energy production while reducing oxidative stress, setting it apart from other mitochondrial-targeted compounds. These findings suggest potential therapeutic applications for diseases characterized by mitochondrial failure and oxidative stress, such as Parkinson’s disease, ALS, and Alzheimer’s disease.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing compounds that target mitochondrial function. The company’s primary product, Telomir-1, is aimed at addressing mitochondrial dysfunction in various diseases, with a market focus on conditions like Hutchinson-Gilford Progeria Syndrome and potentially other diseases involving mitochondrial failure.
Average Trading Volume: 3,104,230
Technical Sentiment Signal: Sell
Current Market Cap: $62.5M
Learn more about TELO stock on TipRanks’ Stock Analysis page.